Market Overview

IntrinsiQ Specialty Solutions' New MarketTREND Tool Provides Unparalleled Market Analysis Reports to Manufacturers

Share:

Drug manufacturers now have timely insights into utilization and
market share of new products

IntrinsiQ Specialty Solutions, a part of AmerisourceBergen, today
announced the launch of MarketTREND, an interactive, visual tool that
provides oncology manufacturers with product performance and market
share analytics on a weekly basis – faster than any other comparable
system on the market. By aggregating real-world treatment data from
community-based private oncology practices, MarketTREND allows
manufacturers direct access to the full context of product usage within
the highly competitive oncology market.

"Historically, pharmaceutical companies have had to wait 30-60 days for
useable utilization and adoption data. With MarketTREND, we can give
this information to manufacturers on a weekly basis," said Susan
Weidner, Senior Vice President of Analytics at IntrinsiQ Specialty
Solutions. "Manufacturers are eager to obtain this type of information,
especially for products that are highly-targeted, entering crowded
markets, or heavily used in the community oncology space. MarketTREND's
reports give manufacturers a significant competitive advantage by
providing the valuable insights needed to make more informed decisions
about their products more quickly."

MarketTREND pulls treatment data from practices' in-office dispensing
and inventory management solutions. That data is compiled in an online
portal, which can be segmented based on the tumor type and/or class of
drug the manufacturer is seeking to analyze. Through this system,
manufacturers can evaluate the drug's uptake, market share (e.g., total
treatment share vs. new patient starts), how it is performing relative
to other drugs in the same category, and how it is affecting the use of
those comparable drugs.

MarketTREND data can be leveraged to identify a need to shift marketing
messages, reevaluate how sales teams are positioning a product for a
particular line of therapy, provide additional education or address
issues around dosing and side effects. With this insight, manufacturers
can conduct outreach and gain valuable feedback on the drug as it is
being used, putting them in the best position to drive utilization over
time.

AmerisourceBergen aims to improve patient outcomes and product
performance through proven solutions for commercialization and channel
management. As part of AmerisourceBergen, IntrinsiQ Specialty Solutions
offers analytics tools that give manufacturers and physician practices
actionable business intelligence to enhance the quality of patient care
and capitalize on market opportunities. For more information about
IntrinsiQ Specialty Solutions, please visit www.intrinsiqanalytics.com/.

About AmerisourceBergen

AmerisourceBergen provides pharmaceutical products, value-driving
services and business solutions that improve access to care. Tens of
thousands of healthcare providers, veterinary practices and livestock
producers trust us as their partner in the pharmaceutical supply chain.
Global manufacturers depend on us for services that drive commercial
success for their products. Through our daily work—and powered by our
21,000 associates—we are united in our responsibility to create
healthier futures. AmerisourceBergen is ranked #12 on the Fortune 500,
with more than $150 billion in annual revenue. The company is
headquartered in Valley Forge, Pa. and has a presence in 50+ countries.
Learn more at amerisourcebergen.com.

View Comments and Join the Discussion!